Drug

DULIGOTUZUMAB

Drug TypeAction TypeMechanism of ActionApprovedMax Trial PhaseMax GBM Phase
Antibody INHIBITOR Receptor tyrosine-protein kinase erbB-3 inhibitor no 2 0